Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138394

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Hang Quach, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Je-Jung Lee, MD PhD, Nichloas Murphy, MBBS, FRACP, FRCPA, Jae Hoon Lee, MD PhD, Kim Kihyun, MD, Jane Estell, FRACP, Noemi Horvath, MB ChB FRACP FRCPA, Richard Eek, FRACP., Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, Rajeev Rajagopal, FRACP, Soo-Mee Bang, MDPhD, Jeffrey SY Huang, MD, PhD, Yoon Sung Soo, MD PhD, Belinda Butcher, BSci, MBiostat, PhD, Brian G.M. Durie, MD, Wee Joo Chng, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139174

Published: 2020

Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3313.

https://doi.org/10.1182/blood.V128.22.3313.3313

Published: 2016

Journal Articles

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Anish Puliyayil Nair, MD DM, FRACP, Cindy Lee, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Jay Hocking, MD PhDstudent, Sue Morgan, FRACP, FRCPA, MBBS, Daniela Klarica, RN, Jenny Muirhead, Andrew Spencer, Oi Lin Lee, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2016) 128 (22): 4684.

https://doi.org/10.1182/blood.V128.22.4684.4684

Published: 2016

Journal Articles

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Robert Z. Orlowski, MD, PhD, Arnon Nagler, MD, Pieter Sonneveld, MDPhD, Joan Bladé, MD PhD, Roman Hajek, Andrew Spencer, MD, Tadeusz Robak, MD, Anna Dmoszynska, Noemi Horvath, MB,ChB, FRACP, FRCPA, Ivan Spicka, Heather J. Sutherland, MD PhD FRCPC, Alexander Suvorov, MD, Liang Xiu, Trilok V. Parekh, PhD, Jesús San Miguel, MD

Blood (2014) 124 (21): 3448.

https://doi.org/10.1182/blood.V124.21.3448.3448

Published: 2014

Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2012) 120 (21): 4065.

https://doi.org/10.1182/blood.V120.21.4065.4065

Published: 2012

Journal Articles

Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?

Annie W.S. Chow, MBBS, Cindy H.S. Lee, MBBS, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Luen Bik To, MBBS, MD, MRCP, FRACP, FRCPA, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2011) 118 (21): 3059.

https://doi.org/10.1182/blood.V118.21.3059.3059

Published: 2011

Journal Articles

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

Noemi Horvath, MB, ChB, FRACP, FRCPA, Douglas E. Joshua, D. Phil FRACP, John Gibson, MD, Andrew W. Roberts, MBBS, PhD, John Norman, MBBS, FRACP, Craig Underhill, MBBS, FRACP, David M. Ross, MBBS, FRACP, FRCPA, Sonya Stephens, Trevor Rawling, Luen B. To, MD

Blood (2005) 106 (11): 5162.

https://doi.org/10.1182/blood.V106.11.5162.5162

Published: 2005

NARROW

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only